Hedge funds have found a new way to make money: challenge a pharma company’s patent on a specific drug and then make a killing as they short the stock and the share price goes weak in the knees. But the long-term prognosis for this investing…
Read More
Latest in Kyle Bass’s Hayman Capital Management Archives - Access International Patent